D

d

Blue Biotech in Portugal: An overview Vitor Vasconcelos

OVERVIEW

Outline

BlueBiotech in Portugal

BlueBio Alliance

CIIMAR Biotechnological R&I

Blue Biotechnology in Portugal

B L U E B I O A L L I A N C E – W H AT W E A R E National Network for collective organization and networking within the BLUE BIORESOURCES sector Accelerate the development of the value chain

B L U E B I O A L L I A N C E – W H AT W E W I S H TO B E VISION To organize all the agents involved in the operation of marine bioresources on a wide network that spans the entire value chain, including producers of raw materials, biotech companies, research units, service providers, the public sector and users of the end products, oriented to the sharing of knowledge and ideas, as well as the boosting of the value chain, to accelerate business growth and strengthen the assertion of Portugal as a leading European country in the advancement and development of marine biotechnology.

BLUEBIO ALLIANCE – HOW WILL WE DO IT? MISSION To support the organization and promotion of the marine bioresources sector value chain

4 ACTION AXES 1. ORGANIZE & PROMOTE Organize and streamline the value chain 2. COLLABORATE & SCALE UP Promote collaboration between players Focus on companies & market 3. GO GLOBAL Internationalize the sector 4. GROW UP Promote funding

BLUEBIO ALLIANCE W HO A R E W E ?

OUR FOUNDING MEMBERS MAIN FOUNDERS AND SPONSORS

94 members across the whole value chain and growing!

Manuel Cavaleiro Ferreira Advogado

Blue Biotech

www.ciimar.up.pt

RESEARCH DOMAINS

3

Research Lines

10 Research Groups

3 Horizon 2020 projects NOMORFILM Novel marine biomolecules against biofilm: Application to medical devices

BLUEandGREEN Boosting scientific excellence and innovation capacity in biorefineries based on marine resources GENIALG GENetic diversity exploitation for Innovative macro-ALGal biorefinery

Description of activities • Marine Biotechnology in CIIMAR deals mostly with the discovery of new bioactive molecules isolated from bacteria, cyanobacteria and fungi.

Cyanobacteria blooms in Portugal

LEGE CULTURE COLLECTION (WFCC 1089) > 400 cyanobacteria strains

Isolation of marine fungi

Identification of the fungi by morphological characteristics

N. siamensis (KUFA 0017)

N. laciniosa (KUFC 7896)

N. spinosa (KUFC 8104)

N. takakii (KUFC 8104)

N. tsunodae (KUFC 9231)

A. similanensis (KUFA 0013)

N. paulistensis (KUFC 7897)

T. trachyspermus (KUFA 21 0021)

Biotechnological approach to cyanobacteria bioactives Culture

Sustainable exploitation of marine microorganisms

Extraction

Green Technologies in biorefinery coproducts

Bioactivity

Production

Bioactivity screening and other multiapproach assays and uses of selected products

Optimization of production processes by biological (fermenters) or chemical (synthesis) approaches

Valorization

Economical valorization of end products and market approach.

CYANOTOXINS

• • • • •

Patterns? Size matters? Diversity within each type Complex metabolic pathways High amounts of toxins produced

PALYTOXIN

MICROCYSTIN

BMAA

ANATOXIN-A SAXITOXIN

CYLINDROSPERMOPSIN

Allelopathy towards plants Effects of MC on Lemna growth and chlorophyll content

Saqrane et al 2007, Aquatic Toxicol. 83:284-294

Toxins versus phytoplankton - MC Chlorella vulgaris

Nannochloropsis

0,7

0,7

0,6

0,6

0,6

0,5

*

*

0,4

*

0,3

. .

0,2 0,1 0,0

.

0,5 0,4 0,3 0,2 0,1 0,0

0

0.04

0.2

0.4

0.8

MC-LR (mg.L-1)

1.6

Growth rate (day-1)

0,7

Growth rate (day-1)

Growth rate (day-1)

Chlamydomonas reinhardtii

*

*

0.8

1.6

0,5

.

0,4 0,3 0,2 0,1 0,0

0

1.2

6.5

11.2 23.9 37.3

MC-LR (mg.L-1)

0

0.04

0.2

0.4

MC-LR (mg.L-1)

Growth rates of the microalgae after 4 (grey bars) and 7 (black bars) days of exposure to pure MCLR. Data significantly different from controls at the fourth (*) and seventh ( ) day of growth (Dunnett’s test, P < 0.05) Pinheiro et al. , 2013. Hydrobiologia 705:27-42

Portoamides – allelopathic compounds from cyanobacteria

Pharmaceuticals

Bioactivity assays – ANTI VIRAL

ANTIMICROBIAL AND ANTICANCERIGENOUS

Patellamide A

Cyanobactins chemical structures

Patellamide A

Tenuecyclamide C

Prochloron spp.

Nostoc spongiaeforme

Lyngbyabactin A

Lyngbya aestuari

Trichamide

Trichodesmium erythraeum Microcyclamide A

Microcystis aeruginosa

Trunkamide

Anacyclamide A10

Anabaena

Prochloron spp. Sivonen et al., 2010

Investing in our common future

Cyanobactin gene clusters published from seven distantly related cyanobacteria (Sivonen et al., 2010) Genes Function: Genes encoding proteases Genes encoding a short precursor peptide Genes encoding proteins involved in the maturation of the cyanobactin Conserved and hypothetical open reading frames

Investing in our common future

patA-like gene ≈ 630 bp

•

Positive Control Freshwater

•

Marine

Lyngbyabactin Microcyclamide, aerucyclamide Microcyclamide Tenuecyclamide Patellamide, lissoclinamide, ulithiacyclamide Patellin, trunkamide

Anacyclamide Trichamide

New Cyanobactins?

Investing in our common future

Antifouling substances Prevent the fouling of marine organisms in: Ships, nets, sensors, and other maritime infrastructures

www.sciencedirect.com -

Take home messages -Natural bloom material and Culture collections are excellent resources and their potential is far from being used. -Chemotyping of cyanobacteria and gene mining allow the discovery of hundreds of new bioactive compounds. -Need to understand ecological role of cyanobacteria and fungi secondary metabolites. -Potential applications in biotechnology are very promising. -International collaboration is needed.

Acknowledgments

Vitor Vasconcelos [email protected]